Related references
Note: Only part of the references are listed.A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer
Ryan J. Sullivan et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Quest for Clinically Effective RAF Dimer Inhibitors
Jenny Y. Xue et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Genetic Heterogeneity of BRAF Fusion Kinases in Melanoma Affects Drug Responses
Thomas Botton et al.
CELL REPORTS (2019)
RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling
Zhan Yao et al.
NATURE MEDICINE (2019)
Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies
Fiona H. Tan et al.
ONCOTARGETS AND THERAPY (2019)
Current Insights of BRAF Inhibitors in Cancer
Bogos Agianian et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
The RUNX1/IL-34/CSF-1R axis is an autocrinally regulated modulator of resistance to BRAF-V600E inhibition in melanoma
Orsi Giricz et al.
JCI INSIGHT (2018)
Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS
Zhan Yao et al.
NATURE (2017)
Polypharmacology-based ceritinib repurposing using integrated functional proteomics
Brent M. Kuenzi et al.
NATURE CHEMICAL BIOLOGY (2017)
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Ahmet Zehir et al.
NATURE MEDICINE (2017)
New perspectives for targeting RAF kinase in human cancer
Zoi Karoulia et al.
NATURE REVIEWS CANCER (2017)
RAS Proteins and Their Regulators in Human Disease
Dhirendra K. Simanshu et al.
CELL (2017)
Absorption, metabolism, and excretion of [14C]ponatinib after a single oral dose in humans
Yihua E. Ye et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling
Zoi Karoulia et al.
CANCER CELL (2016)
Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinases
Krisna C. Duong-Ly et al.
CELL REPORTS (2016)
Inhibition of RAF lsoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers
Sheng-Bin Peng et al.
CANCER CELL (2015)
BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition
Zhan Yao et al.
CANCER CELL (2015)
RAF inhibitors that evade paradoxical MAPK pathway activation
Chao Zhang et al.
NATURE (2015)
Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation
Tea Pemovska et al.
NATURE (2015)
Regulation of RAF protein kinases in ERK signalling
Hugo Lavoie et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2015)
Crystal structure of a BRAF kinase domain monomer explains basis for allosteric regulation
Neroshan Thevakumaran et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2015)
Structure of the BRAF-MEK Complex Reveals a Kinase Activity Independent Role for BRAF in MAPK Signaling
Jacob R. Haling et al.
CANCER CELL (2014)
KLIFS: A Knowledge-Based Structural Database To Navigate Kinase-Ligand Interaction Space
Oscar P. J. van Linden et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Targeting RAS-ERK signalling in cancer: promises and challenges
Ahmed A. Samatar et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond
Matthew Holderfield et al.
NATURE REVIEWS CANCER (2014)
Resistance to BRAF-targeted therapy in melanoma
Ryan J. Sullivan et al.
EUROPEAN JOURNAL OF CANCER (2013)
Discovery of a Selective Kinase Inhibitor (TAK-632) Targeting Pan-RAF Inhibition: Design, Synthesis, and Biological Evaluation of C-7-Substituted 1,3-Benzothiazole Derivatives
Masanori Okaniwa et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Tumor adaptation and resistance to RAF inhibitors
Piro Lito et al.
NATURE MEDICINE (2013)
Collaboration gets the most out of software
Andrew Morin et al.
ELIFE (2013)
Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models
Joseph M. Gozgit et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases
E. Lierman et al.
LEUKEMIA (2012)
Vemurafenib: the first drug approved for BRAF-mutant cancer
Gideon Bollag et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Evolution of the eukaryotic protein kinases as dynamic molecular switches
Susan S. Taylor et al.
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES (2012)
iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM
T. Geoff G. Battye et al.
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY (2011)
Overview of the CCP4 suite and current developments
Martyn D. Winn et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2011)
Potent Activity of Ponatinib (AP24534) in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies
Joseph M. Gozgit et al.
MOLECULAR CANCER THERAPEUTICS (2011)
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikos I. Poulikakos et al.
NATURE (2011)
Comprehensive analysis of kinase inhibitor selectivity
Mindy I. Davis et al.
NATURE BIOTECHNOLOGY (2011)
Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
Jessie Villanueva et al.
CANCER CELL (2010)
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Sonja J. Heidorn et al.
CELL (2010)
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikos I. Poulikakos et al.
NATURE (2010)
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Georgia Hatzivassiliou et al.
NATURE (2010)
Melanomas acquire resistance toB-RAF(V600E) inhibition by RTK or N-RAS upregulation
Ramin Nazarian et al.
NATURE (2010)
Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?
Dominico Vigil et al.
NATURE REVIEWS CANCER (2010)
AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
Thomas O'Hare et al.
CANCER CELL (2009)
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
P. J. Roberts et al.
ONCOGENE (2007)
PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results
Steven L. Dixon et al.
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN (2006)
Coordinating ERK/MAPK signalling through scaffolds and inhibitors
W Kolch
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2005)
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF
PTC Wan et al.
CELL (2004)
The RAF proteins take centre stage
C Wellbrock et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Share Paper
